<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03447132</url>
  </required_header>
  <id_info>
    <org_study_id>ICRG1201</org_study_id>
    <nct_id>NCT03447132</nct_id>
  </id_info>
  <brief_title>Fulvestrant Versus Fulvestrant Plus Palbociclib in Operable Breast Cancer Responding to Fulvestrant</brief_title>
  <acronym>SAFIA</acronym>
  <official_title>Multicentre, International Neoadjuvant Randomized Double-blind Trial Comparing Fulvestrant® to a Combination of Fulvestrant® and Palbociclib (CDK 4/6 Inhibitor) in Patients With Operable Luminal Breast Cancer Responding to Fulvestrant®</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>International Cancer Research Group, United Arab Emirates</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Genomic Health®, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>International Cancer Research Group, United Arab Emirates</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, international, double-blind randomized Phase III study to evaluate the&#xD;
      pathological complete response (pCR) according to Chevalier classification between&#xD;
      Fulvestrant® and the combination of Fulvestrant® plus Palbociclib as neoadjuvant therapy of&#xD;
      hormone-sensitive patients with operable luminal breast cancer.&#xD;
&#xD;
      Eligible patients will be assessed upfront using the OncotypeDX® molecular test (Recurrence&#xD;
      Score &lt;31).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multicenter, international, double-blind, randomized study.&#xD;
&#xD;
      Eligible patients based on inclusion/exclusion criteria will be assessed using OncotypeDX&#xD;
      molecular test. Patients with low/intermediate risk (Recurrence Score &lt;31) will be treated&#xD;
      with the induction neoadjuvant Fulvestrant (500 mg (milligram) intra muscular(i.m) at Day 1,&#xD;
      14 and 28 and then every 4 weeks), plus Goserelin (3.6 mg subcutaneous (s.c) every 4 weeks,&#xD;
      only for pre and peri-menopausal patients) for 4 months, followed by clinical and&#xD;
      radiological assessment of the disease response.&#xD;
&#xD;
      Patients with objective response or stabilization will be randomized and treated for 4&#xD;
      additional months with:&#xD;
&#xD;
        -  Fulvestrant 500 mg i.m every 4 weeks (+ Goserelin 3.6 mg s.c every 4 weeks, only for pre&#xD;
           and peri-menopausal patients) and Placebo&#xD;
&#xD;
      or&#xD;
&#xD;
        -  Combination Fulvestrant 500 mg i.m every 4 weeks (+ Goserelin 3.6 mg s.c every 4 weeks,&#xD;
           only for pre and peri-menopausal patients) and Palbociclib 125 mg per os daily, 3 weeks&#xD;
           on and 1 week off.&#xD;
&#xD;
      Patients with documented progressive disease will be considered at the discretion of the&#xD;
      investigator for surgery or neoadjuvant chemotherapy. The preferred chemotherapy protocol&#xD;
      will be FEC 100 -Taxotere (5fluorouracil 500mg/m2, Epirubicin 100 mg/m2, cyclophosphamide 500&#xD;
      mg/m2 (FEC) q3 weeks for 3 cycles followed by Docetaxel 100 mg/m2 (T) q 3 weeks for 3 cycles)&#xD;
      for a total of 6 cycles with clinical and radiological assessment after each 3 cycles of&#xD;
      chemotherapy (CT). Chemotherapy candidates will as well undergo surgery. The expected&#xD;
      interval between the cycles will be 21 days, unless the patient has not recovered from&#xD;
      toxicity. Specific dose adjustments will be set out in the protocol.&#xD;
&#xD;
      Breast and nodal surgery will be performed at completion of therapy (8 months of hormonal&#xD;
      therapy for responding patients and 6 additional cycles of CT for non-responders). The type&#xD;
      of surgery will be left at the discretion of the investigators.&#xD;
&#xD;
      Radiation therapy and adjuvant systemic treatment and endocrine therapy will be as well left&#xD;
      at the discretion of the investigators.&#xD;
&#xD;
      Patients will be followed every 6 months during 5 years post surgery.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2018</start_date>
  <completion_date type="Anticipated">September 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>pCR according to Le Chevalier's classification</measure>
    <time_frame>up to 5 years after the end of treatment period</time_frame>
    <description>pathological complete response will be assessed according to Le Chevalier's classification between two arms</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>pCR according to Sataloff's classification</measure>
    <time_frame>up to 5 years after the end of treatment period</time_frame>
    <description>pathological complete response will be assessed according to Sataloff's classification between two arms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>radiological response</measure>
    <time_frame>up to 5 years after the end of treatment period</time_frame>
    <description>radiological response according to the WHO criteria (US/Mammography/MRI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of breast conservative surgery</measure>
    <time_frame>up to 5 years after the end of treatment period</time_frame>
    <description>Rate of breast conservative surgery will be assessed and compared between two arms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety /Tolerability of the combination Fulvestrant + Palbociclib</measure>
    <time_frame>up to 5 years after the end of treatment period</time_frame>
    <description>Safety and tolerability will be assessed in terms of adverse events (AEs), laboratory data and vital signs. Treatment-related adverse events will be assessed by using CTCAE v4.1 classification</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DFS and OS</measure>
    <time_frame>up to 5 years after the end of treatment period</time_frame>
    <description>Evaluation and comparison of Disease Free Survival (DFS) and Overall Survival (OS) between two arms</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Breast Neoplasm Female</condition>
  <arm_group>
    <arm_group_label>Fulvestrant 500mg + Palbociclib 125mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>+ Goserelin 3.6 mg if pre or peri menopausal patient - duration 4 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fulvestrant 500mg + Placebos</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>+ Goserelin 3.6 mg if pre or peri menopausal patient - duration 4 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fulvestrant 500mg</intervention_name>
    <description>All patients in all arms will receive Fulvestrant 500mg</description>
    <arm_group_label>Fulvestrant 500mg + Palbociclib 125mg</arm_group_label>
    <arm_group_label>Fulvestrant 500mg + Placebos</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Palbociclib 125mg</intervention_name>
    <description>Dose reduction to 100 mg and 75 mg</description>
    <arm_group_label>Fulvestrant 500mg + Palbociclib 125mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Goserelin 3.6 MG</intervention_name>
    <description>Only for pre or peri menopausal patient</description>
    <arm_group_label>Fulvestrant 500mg + Palbociclib 125mg</arm_group_label>
    <arm_group_label>Fulvestrant 500mg + Placebos</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebos</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Fulvestrant 500mg + Placebos</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Written informed consent prior to beginning specific protocol procedures including&#xD;
             expected cooperation of the patients for the treatment and follow-up must be obtained&#xD;
             and documented according to the local regulatory requirements.&#xD;
&#xD;
          2. Age &gt;18.&#xD;
&#xD;
          3. Postmenopausal women or pre-menopausal (with medical or surgical oophorectomy)&#xD;
&#xD;
          4. Performance status &lt; 2 (according to WHO criteria).&#xD;
&#xD;
          5. Histologically confirmed non-metastatic breast cancer (Luminal A or B)&#xD;
&#xD;
               -  HR (hormone receptor ) positive (Estrogen or Progesterone)&gt; 1%.&#xD;
&#xD;
               -  Her-2 negative (score 0 or 1 by immunochemistry), FISH (fluorescence in situ&#xD;
                  hybridization) negative if IHC (immuno-histochemistry) score 2).&#xD;
&#xD;
          6. Clinical stage II and IIIa.&#xD;
&#xD;
          7. No previous breast cancer treatment by surgery, radiotherapy, hormone therapy or&#xD;
             chemotherapy.&#xD;
&#xD;
          8. Measurable or evaluable disease.&#xD;
&#xD;
          9. Hematology:&#xD;
&#xD;
               -  Neutrophil count ≥ 1.5 G/L.&#xD;
&#xD;
               -  Platelet count ≥ 100 G/L.&#xD;
&#xD;
               -  Leucocyte count &gt; 3.0 G/L.&#xD;
&#xD;
               -  Hb&gt; 9g/dl.&#xD;
&#xD;
         10. Hepatic function:&#xD;
&#xD;
               -  Total bilirubin ≤ 1.5 time the Upper Normal Limit (UNL).&#xD;
&#xD;
               -  ASAT (alanine aminotransferase aspartate transaminase ) ≤ 2.5xUNL.&#xD;
&#xD;
               -  ALAT (alanine aminotransferase) ≤ 2.5xUNL.&#xD;
&#xD;
               -  Alkaline phosphatase ≤ 2.5 time the upper normal limit (UNL).&#xD;
&#xD;
         11. Renal function:&#xD;
&#xD;
               -  Serum creatinine ≤1.5xUNL (and if Serum creatinine &gt;1.5xUNL, creatinine clearance&#xD;
                  ≥50 mL/min).&#xD;
&#xD;
               -  Creatinine clearance ≥40 mL/min in case of MRI.&#xD;
&#xD;
         12. Metabolic function:&#xD;
&#xD;
               -  Serum magnesium ≥ lower limit of normal.&#xD;
&#xD;
               -  Serum calcium ≥ lower limit of normal.&#xD;
&#xD;
         13. No progressive heart disease and no anthracycline contraindication (normal LVEF ( left&#xD;
             ventricular ejection fraction) according to the institution guidelines).&#xD;
&#xD;
         14. Negative pregnancy test (urine or serum) within 7 days prior to registration for all&#xD;
             women of childbearing potential. Patients of childbearing potential must implement&#xD;
             adequate non-hormonal contraceptive measures during study treatment.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Male patients.&#xD;
&#xD;
          2. Her-2 positive tumors or unknown HR/Her-2 status.&#xD;
&#xD;
          3. Pregnancy or breast-feeding, or plan to become pregnant within 6 months post&#xD;
             treatment.&#xD;
&#xD;
          4. No willingness to use highly effective methods of contraception (per institutional&#xD;
             standard) during treatment and for 6 months post treatment.&#xD;
&#xD;
          5. Any form of breast cancer other than those described in the inclusion criteria,&#xD;
             particularly inflammatory and/or overlooked forms (stages IIIb or IV).&#xD;
&#xD;
          6. Non-measurable tumour.&#xD;
&#xD;
          7. Bilateral breast cancer.&#xD;
&#xD;
          8. Previous treatment for breast cancer including surgery for their disease or have had&#xD;
             primary axillary dissection, radiotherapy and systemic therapy.&#xD;
&#xD;
          9. Patient with history of other cancer, except in situ cervical cancer or baso-cellular&#xD;
             skin cancer, considered cured.&#xD;
&#xD;
         10. Patient has another disease, which is deemed incompatible with the inclusion in the&#xD;
             protocol.&#xD;
&#xD;
         11. Heart, kidney, medullary, respiratory or liver failure. Clinically significant&#xD;
             cardiovascular disease (including myocardial infarction, unstable angina, symptomatic&#xD;
             congestive heart failure, serious uncontrolled cardiac arrhythmia) ≤ 1 year before&#xD;
             enrollment in the study.&#xD;
&#xD;
               -  History of interstitial lung disease e.g. pneumonitis or pulmonary fibrosis or&#xD;
                  evidence of interstitial lung disease at baseline&#xD;
&#xD;
               -  Acute urinary infection, ongoing hemorrhagic cystitis.&#xD;
&#xD;
         12. Uncontrolled diabetes.&#xD;
&#xD;
         13. Symptomatic or progressive disorder of the central nervous system (CNS) Peripheral&#xD;
             neuropathy &gt; grade 2&#xD;
&#xD;
         14. Significant psychiatric abnormalities.&#xD;
&#xD;
         15. History of hypersensitivity to studied treatment or excipients&#xD;
&#xD;
         16. Known previous or ongoing abuse narcotic drug, other medication or alcohol&#xD;
&#xD;
         17. Any investigational agent within 30 days before initiation of study treatment.&#xD;
&#xD;
         18. No major surgical procedure within 28 days of initiation of treatment.&#xD;
&#xD;
         19. Subject unwilling or unable to comply with study requirement.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-Marc Nabholtz, MD</last_name>
    <role>Study Chair</role>
    <affiliation>International Cancer Research Group</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Abdelaziz FAHEM, PhD</last_name>
    <phone>+971582873250</phone>
    <email>abdelaziz.fahem@hotmail.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sharif Kullab, MD</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Center Pierre et Marie Curie</name>
      <address>
        <city>Algiers</city>
        <country>Algeria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cancer Center - Blida</name>
      <address>
        <city>Blida</city>
        <country>Algeria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU - Oran</name>
      <address>
        <city>Oran</city>
        <country>Algeria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Alexandria</name>
      <address>
        <city>Alexandria</city>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>National Cancer Institut (NCI)</name>
      <address>
        <city>Cairo</city>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>King Hussein Cancer Center (KHCC) - Amman</name>
      <address>
        <city>Amán</city>
        <country>Jordan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hotel Dieu de France</name>
      <address>
        <city>Beyrouth</city>
        <country>Lebanon</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hopital Cheikh Khalifa Ibn Zaid</name>
      <address>
        <city>Casablanca</city>
        <country>Morocco</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Department of Oncology - Institut National d'Oncologie</name>
      <address>
        <city>Rabat</city>
        <country>Morocco</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>King Abdul Aziz Medical City-National Guard Health Affairs (NGHA)</name>
      <address>
        <city>Riyadh</city>
        <country>Saudi Arabia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Oncology Center- King Fahad Medical City (KFMC)</name>
      <address>
        <city>Riyadh</city>
        <country>Saudi Arabia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Oncology Center- King Saud University Medical City (KSUMC)</name>
      <address>
        <city>Riyadh</city>
        <country>Saudi Arabia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Oncologie Medicale de l'Ariana (SOMA)</name>
      <address>
        <city>Tunis</city>
        <country>Tunisia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tawam Hospital</name>
      <address>
        <city>Al Ain</city>
        <country>United Arab Emirates</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Fathi Azribi, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Algeria</country>
    <country>Egypt</country>
    <country>Jordan</country>
    <country>Lebanon</country>
    <country>Morocco</country>
    <country>Saudi Arabia</country>
    <country>Tunisia</country>
    <country>United Arab Emirates</country>
  </location_countries>
  <verification_date>November 2018</verification_date>
  <study_first_submitted>February 11, 2018</study_first_submitted>
  <study_first_submitted_qc>February 25, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 27, 2018</study_first_posted>
  <last_update_submitted>November 8, 2018</last_update_submitted>
  <last_update_submitted_qc>November 8, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">November 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Breast Cancer</keyword>
  <keyword>Luminal</keyword>
  <keyword>Neoadjuvant</keyword>
  <keyword>pCR</keyword>
  <keyword>Surgery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fulvestrant</mesh_term>
    <mesh_term>Goserelin</mesh_term>
    <mesh_term>Palbociclib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

